Showing results (491-500 of 572) with videos related to
Sort By:
Pageof 58
Journal of the American Society of Nephrology : JASN|July 12, 2019
Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational DataMorgan E Grams, Yingying Sang, Shoshana H Ballew, et al.Journal of the American Society of Nephrology : JASN|May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized TrialMeg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.Kidney360|April 9, 2025
Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation: A Binational Population-Based StudyDickson Lam, Anish Scaria, Jason Andrade, et al.Nature Medicine|May 25, 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.Canadian Journal of Kidney Health and Disease|June 2, 2026
Integrated, Community-Led, Culturally Safe Implementation of a Chronic Kidney Disease Detection Program for Indigenous Communities of Canada: The Kidney Check Program ReportSomkanya Tungsanga, Cathy Woods, Selina Allu, et al.Kidney International Supplements|April 15, 2024
Capacity for the management of kidney failure in the International Society of Nephrology South Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)Eranga Wijewickrama, Muhammad Rafiqul Alam, Divya Bajpai, et al.Kidney International|October 1, 2020
International consensus definitions of clinical trial outcomes for kidney failure: 2020Adeera Levin, Rajiv Agarwal, William G Herrington, et al.The New England Journal of Medicine|April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg J Jardine, Bruce Neal, et al.Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.Kidney Medicine|July 26, 2023
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and CanadaJeffrey T Ha, Anish Scaria, Jason Andrade, et al.Pageof 58